What is the equity of GenKyoTex this year?
GenKyoTex has equity of 0 this year.
GenKyoTex Equity 2024
GenKyoTex Equity
0
Ticker
GKTX.PA
ISIN
FR0013399474
WKN
A2PE0M
In 2024, GenKyoTex's equity was 0 , a 0% increase from the 0 equity in the previous year.
GenKyoTex Aktienanalyse
What does GenKyoTex do?
GenKyoTex SA is a Swiss biotechnology company specializing in the development of innovative therapies for the treatment of inflammatory diseases. The company was founded in 2006 by Dr. Elias Papatheodorou and Dr. Takashi Mizuno and is headquartered near Lausanne. The history of GenKyoTex SA began with the discovery of a new enzyme called NOX (NADPH oxidase) 1/4, which plays a crucial role in the onset of inflammation. This was the starting point for the development of inhibitors that reduce NOX activity and thus halt the progression of inflammatory diseases such as fibrosis, arthritis, or kidney failure. GenKyoTex SA's business model is based on the development and marketing of therapeutics based on NOX inhibitor technology. The company works closely with leading experts and research institutions to develop innovative drugs and conduct clinical trials. The different divisions of GenKyoTex SA include expertise in formulation, manufacturing, and stabilization of active ingredients and drugs, as well as the development of clinical trials and optimization of production processes. The company has its own research and development department, allowing it to oversee the entire value chain associated with its products. The company has developed a range of products based on NOX inhibitor technology. One of these is GKT831, a drug used to treat patients with idiopathic pulmonary fibrosis (IPF). IPF is a chronic and progressive condition in which lung tissue becomes inflamed and scarred, impairing oxygen uptake. GKT831 has shown promising results in a clinical program. Another product from GenKyoTex SA is GKT771, a drug used to treat patients with diabetic nephropathy. Diabetic nephropathy is a complication of diabetes in which kidney function deteriorates. GKT771 has shown positive results in a phase 2 study and is now in phase 3 development. Overall, GenKyoTex SA is an innovative company focused on the development of drugs for the treatment of inflammation. The company has expertise in NOX inhibitor technology and has already brought several promising products to market or in development. Thanks to collaboration with leading experts and research institutions, GenKyoTex SA can accelerate the development of new drugs and improve patients' quality of life. GenKyoTex ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing GenKyoTex's Equity
GenKyoTex's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding GenKyoTex's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating GenKyoTex's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
GenKyoTex's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in GenKyoTex’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about GenKyoTex stock
What was the equity of GenKyoTex compared to the previous year?
The equity of GenKyoTex has increased/decreased by 0% decreased compared to the previous year.
What impact does a high equity have on investors of GenKyoTex?
A high equity is advantageous for investors of GenKyoTex as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of GenKyoTex?
A low equity can be a risk for investors of GenKyoTex, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of GenKyoTex affect the company?
An increase in equity of GenKyoTex can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of GenKyoTex affect the company?
A reduction in equity of GenKyoTex can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of GenKyoTex?
Some factors that can affect the equity of GenKyoTex include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of GenKyoTex so important for investors?
The equity of GenKyoTex is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can GenKyoTex take to change the equity?
To change equity, GenKyoTex can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does GenKyoTex pay?
Over the past 12 months, GenKyoTex paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, GenKyoTex is expected to pay a dividend of 0 .
What is the dividend yield of GenKyoTex?
The current dividend yield of GenKyoTex is .
When does GenKyoTex pay dividends?
GenKyoTex pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of GenKyoTex?
GenKyoTex paid dividends every year for the past 0 years.
What is the dividend of GenKyoTex?
For the upcoming 12 months, dividends amounting to 0 are expected. This corresponds to a dividend yield of 0 %.
In which sector is GenKyoTex located?
GenKyoTex is assigned to the 'Health' sector.
Wann musste ich die Aktien von GenKyoTex kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of GenKyoTex from 9/18/2024 amounting to 0 , you needed to have the stock in your portfolio before the ex-date on 9/18/2024.
When did GenKyoTex pay the last dividend?
The last dividend was paid out on 9/18/2024.
What was the dividend of GenKyoTex in the year 2023?
In the year 2023, GenKyoTex distributed 0 as dividends.
In which currency does GenKyoTex pay out the dividend?
The dividends of GenKyoTex are distributed in .
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von GenKyoTex
Our stock analysis for GenKyoTex Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GenKyoTex Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
